ondansetron has been researched along with Hyperemesis Gravidarum in 33 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Hyperemesis Gravidarum: Intractable VOMITING that develops in early PREGNANCY and persists. This can lead to DEHYDRATION and WEIGHT LOSS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this small trial, gabapentin was more effective than standard-of-care therapy for reducing nausea and vomiting and increasing oral nutrition and global satisfaction in outpatients with hyperemesis gravidarum." | 9.41 | Effect of gabapentin on hyperemesis gravidarum: a double-blind, randomized controlled trial. ( Guttuso, T; Messing, S; Mullin, P; Saha, S; Shepherd, R; Strittmatter, C; Thornburg, LL; Tu, X, 2021) |
| " One hundred and eighty pregnant women referred to secondary care for hyperemesis gravidarum will be randomly allocated to 14-day treatment with either mirtazapine, ondansetron or placebo." | 9.34 | Validating the effect of Ondansetron and Mirtazapine In Treating hyperemesis gravidarum (VOMIT): protocol for a randomised placebo-controlled trial. ( Andersen, JT; Futtrup, TB; Jensen, AK; Løkkegaard, ECL; Ostenfeld, A; Pedersen, LH; Petersen, TS; Westergaard, HB, 2020) |
| "To compare ondansetron with metoclopramide in the treatment of hyperemesis gravidarum." | 9.19 | Ondansetron compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. ( Abas, MN; Azmi, N; Omar, SZ; Tan, PC, 2014) |
| "To evaluate whether ondansetron or the combination of doxylamine and pyridoxine was superior for the treatment of nausea and vomiting of pregnancy." | 9.19 | Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial. ( Capp, SM; Carstairs, SD; Oliveira, LG; Riffenburgh, RH; You, WB, 2014) |
| " Diazepam and benzodiazepines have been widely studied in pregnancy but the results are contradictory." | 9.09 | Evaluation of treatment of hyperemesis gravidarum using parenteral fluid with or without diazepam. A randomized study. ( De Leo, V; Ditto, A; la Marca, A; Morgante, G, 1999) |
| "This preliminary trial of ondansetron demonstrated no benefit over promethazine in patients hospitalized for hyperemesis gravidarum." | 9.08 | A pilot study of intravenous ondansetron for hyperemesis gravidarum. ( Johnson, CA; Martin, RW; Morrison, JC; Roach, H; Stewart, DK; Sullivan, CA, 1996) |
| "Ondansetron, not approved for use in pregnancy, is increasingly being prescribed for nausea and vomiting in pregnancy and hyperemesis gravidarum." | 8.98 | Ondansetron in Pregnancy and the Risk of Congenital Malformations: A Systematic Review. ( Campbell, S; Chari, R; Lavecchia, M; Ross, S, 2018) |
| "To examine the risk of birth defects in children born to women who used ondansetron early in pregnancy for nausea and vomiting of pregnancy or hyperemesis gravidarum." | 8.93 | Ondansetron Use in Pregnancy and Birth Defects: A Systematic Review. ( Carstairs, SD, 2016) |
| "Ondansetron is a widely administered medication for nausea and vomiting of pregnancy." | 8.31 | Ondansetron Use During Pregnancy: Birth Defects and Obstetric Outcomes. ( Azab, AN; Betesh-Abay, B; Hadar, E; Masarwe, S; Peleg, N; Shvartsur, R, 2023) |
| "This is an analysis of fetal outcome in pregnancies exposed to ondansetron to treat Hyperemesis Gravidarum (HG)." | 7.83 | Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States. ( Fejzo, MS; MacGibbon, KW; Mullin, PM, 2016) |
| "Our study did not detect any adverse outcomes from the use of ondansetron in pregnancy but could not conclude that ondansetron is safe to use in pregnancy." | 7.79 | Off-label use of ondansetron in pregnancy in Western Australia. ( Bower, C; Colvin, L; Gill, AW; Slack-Smith, L; Stanley, FJ, 2013) |
| "This is a descriptive retrospective case series of 14 pregnant women treated with ondansetron for hyperemesis gravidarum (HG) at CHU Sainte-Justine, from January 2002 to October 2011." | 7.78 | Ondansetron use during pregnancy: a case series. ( Bussières, JF; Ferreira, E; Gillet, M; Lelièvre, J, 2012) |
| " There are numerous limitations in the current literature on ondansetron safety including exposure to the medication is not limited to sensitive windows of organogenesis, there is a lack of information on dosing and compliance, self-reports of exposure are commonly used, an inadequate accounting exists for other factors that may explain the relationship between ondansetron exposure and the adverse outcome, and there exists a lack of biologic plausibility by which ondansetron might cause harm." | 5.43 | Ondansetron Use in Pregnancy. ( Bodnar, LM; Caritis, SN; Siminerio, LL; Venkataramanan, R, 2016) |
| "In this small trial, gabapentin was more effective than standard-of-care therapy for reducing nausea and vomiting and increasing oral nutrition and global satisfaction in outpatients with hyperemesis gravidarum." | 5.41 | Effect of gabapentin on hyperemesis gravidarum: a double-blind, randomized controlled trial. ( Guttuso, T; Messing, S; Mullin, P; Saha, S; Shepherd, R; Strittmatter, C; Thornburg, LL; Tu, X, 2021) |
| " One hundred and eighty pregnant women referred to secondary care for hyperemesis gravidarum will be randomly allocated to 14-day treatment with either mirtazapine, ondansetron or placebo." | 5.34 | Validating the effect of Ondansetron and Mirtazapine In Treating hyperemesis gravidarum (VOMIT): protocol for a randomised placebo-controlled trial. ( Andersen, JT; Futtrup, TB; Jensen, AK; Løkkegaard, ECL; Ostenfeld, A; Pedersen, LH; Petersen, TS; Westergaard, HB, 2020) |
| "Hyperemesis gravidarum is a disabling condition." | 5.31 | Treatment of intractable hyperemesis gravidarum by ondansetron. ( Cheung, CW; Lau, TK; Siu, SS; Yip, SK, 2002) |
| "Ondansetron is a 5-hydroxytryptamine receptor antagonist which is known to be a highly effective anti-emetic drug for chemotherapy-associated nausea and vomiting and for postoperative nausea." | 5.29 | Treatment of hyperemesis gravidarum with the 5-HT3 antagonist ondansetron (Zofran). ( Johnstone, MJ; Tincello, DG, 1996) |
| "To compare ondansetron with metoclopramide in the treatment of hyperemesis gravidarum." | 5.19 | Ondansetron compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. ( Abas, MN; Azmi, N; Omar, SZ; Tan, PC, 2014) |
| "To evaluate whether ondansetron or the combination of doxylamine and pyridoxine was superior for the treatment of nausea and vomiting of pregnancy." | 5.19 | Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial. ( Capp, SM; Carstairs, SD; Oliveira, LG; Riffenburgh, RH; You, WB, 2014) |
| " Diazepam and benzodiazepines have been widely studied in pregnancy but the results are contradictory." | 5.09 | Evaluation of treatment of hyperemesis gravidarum using parenteral fluid with or without diazepam. A randomized study. ( De Leo, V; Ditto, A; la Marca, A; Morgante, G, 1999) |
| "This preliminary trial of ondansetron demonstrated no benefit over promethazine in patients hospitalized for hyperemesis gravidarum." | 5.08 | A pilot study of intravenous ondansetron for hyperemesis gravidarum. ( Johnson, CA; Martin, RW; Morrison, JC; Roach, H; Stewart, DK; Sullivan, CA, 1996) |
| "Ondansetron, not approved for use in pregnancy, is increasingly being prescribed for nausea and vomiting in pregnancy and hyperemesis gravidarum." | 4.98 | Ondansetron in Pregnancy and the Risk of Congenital Malformations: A Systematic Review. ( Campbell, S; Chari, R; Lavecchia, M; Ross, S, 2018) |
| " (June issue of Reproductive Toxicology) on the relationship of ondansetron exposure to pregnancy outcome and birth defects." | 4.95 | Publishing negative findings and the challenge of avoiding type II errors in studies of suspect teratogens: Example of a recent ondansetron publication. ( Edlavitch, SA, 2017) |
| "For mild symptoms of nausea and emesis of pregnancy, ginger, pyridoxine, antihistamines, and metoclopramide were associated with greater benefit than placebo." | 4.93 | Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review. ( Beyer, F; Bradley, J; Bryant, A; McParlin, C; Moloney, E; Muirhead, CR; Nelson-Piercy, C; Newbury-Birch, D; Norman, J; O'Donnell, A; Robson, SC; Shaw, C; Simpson, E; Swallow, B; Vale, L; Yates, L, 2016) |
| "To examine the risk of birth defects in children born to women who used ondansetron early in pregnancy for nausea and vomiting of pregnancy or hyperemesis gravidarum." | 4.93 | Ondansetron Use in Pregnancy and Birth Defects: A Systematic Review. ( Carstairs, SD, 2016) |
| "Ondansetron is a widely administered medication for nausea and vomiting of pregnancy." | 4.31 | Ondansetron Use During Pregnancy: Birth Defects and Obstetric Outcomes. ( Azab, AN; Betesh-Abay, B; Hadar, E; Masarwe, S; Peleg, N; Shvartsur, R, 2023) |
| "This is an analysis of fetal outcome in pregnancies exposed to ondansetron to treat Hyperemesis Gravidarum (HG)." | 3.83 | Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States. ( Fejzo, MS; MacGibbon, KW; Mullin, PM, 2016) |
| "Our study did not detect any adverse outcomes from the use of ondansetron in pregnancy but could not conclude that ondansetron is safe to use in pregnancy." | 3.79 | Off-label use of ondansetron in pregnancy in Western Australia. ( Bower, C; Colvin, L; Gill, AW; Slack-Smith, L; Stanley, FJ, 2013) |
| " For morning sickness, 89% of those replying give dietary advice frequently or always, and 70% prescribe metoclopramide frequently or always, whereas 59% advise pyridoxine and 10% prescribe doxylamine." | 3.79 | A survey of prescribing for the management of nausea and vomiting in pregnancy in Australasia. ( Raymond, SH, 2013) |
| "This is a descriptive retrospective case series of 14 pregnant women treated with ondansetron for hyperemesis gravidarum (HG) at CHU Sainte-Justine, from January 2002 to October 2011." | 3.78 | Ondansetron use during pregnancy: a case series. ( Bussières, JF; Ferreira, E; Gillet, M; Lelièvre, J, 2012) |
| "Hyperemesis gravidarum is a severe form of nausea and vomiting in pregnancy affecting 0." | 2.53 | Interventions for treating hyperemesis gravidarum. ( Barton, SJ; Berghella, V; Boelig, RC; Edwards, SJ; Kelly, AJ; Saccone, G, 2016) |
| "Of note, co-existing gastroesophageal reflux disease (GERD), Helicobacter pylori infection, and psychosocial factors may have a negative impact on the management of NVP." | 2.50 | The outpatient management and special considerations of nausea and vomiting in pregnancy. ( Clark, SM; Dutta, E; Hankins, GD, 2014) |
| " There are numerous limitations in the current literature on ondansetron safety including exposure to the medication is not limited to sensitive windows of organogenesis, there is a lack of information on dosing and compliance, self-reports of exposure are commonly used, an inadequate accounting exists for other factors that may explain the relationship between ondansetron exposure and the adverse outcome, and there exists a lack of biologic plausibility by which ondansetron might cause harm." | 1.43 | Ondansetron Use in Pregnancy. ( Bodnar, LM; Caritis, SN; Siminerio, LL; Venkataramanan, R, 2016) |
| "A client could have weight loss, dehydration, nutritional deficiencies, metabolic deficiencies, difficulty with daily activities, psychosocial stress and depression." | 1.35 | A case study approach to Hyperemesis Gravidarum: home care implications. ( Jennings-Sanders, A, 2009) |
| "Hyperemesis gravidarum is a disabling condition." | 1.31 | Treatment of intractable hyperemesis gravidarum by ondansetron. ( Cheung, CW; Lau, TK; Siu, SS; Yip, SK, 2002) |
| "Ondansetron is a 5-hydroxytryptamine receptor antagonist which is known to be a highly effective anti-emetic drug for chemotherapy-associated nausea and vomiting and for postoperative nausea." | 1.29 | Treatment of hyperemesis gravidarum with the 5-HT3 antagonist ondansetron (Zofran). ( Johnstone, MJ; Tincello, DG, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (15.15) | 18.2507 |
| 2000's | 4 (12.12) | 29.6817 |
| 2010's | 18 (54.55) | 24.3611 |
| 2020's | 6 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Masarwe, S | 1 |
| Shvartsur, R | 1 |
| Hadar, E | 1 |
| Betesh-Abay, B | 1 |
| Peleg, N | 1 |
| Azab, AN | 1 |
| Ostenfeld, A | 1 |
| Petersen, TS | 1 |
| Futtrup, TB | 1 |
| Andersen, JT | 1 |
| Jensen, AK | 1 |
| Westergaard, HB | 1 |
| Pedersen, LH | 1 |
| Løkkegaard, ECL | 1 |
| Kirby, RS | 1 |
| Damkier, P | 1 |
| Kaplan, YC | 1 |
| Shechtman, S | 1 |
| Diav-Citrin, O | 1 |
| Cassina, M | 1 |
| Weber-Schoendorfer, C | 1 |
| Cleary, B | 1 |
| Hodson, K | 1 |
| Guttuso, T | 1 |
| Messing, S | 1 |
| Tu, X | 1 |
| Mullin, P | 1 |
| Shepherd, R | 1 |
| Strittmatter, C | 1 |
| Saha, S | 1 |
| Thornburg, LL | 1 |
| Moussa, G | 1 |
| Genest, M | 1 |
| Villeneuve, E | 1 |
| Wang, JJ | 1 |
| Lavecchia, M | 2 |
| Chari, R | 2 |
| Campbell, S | 1 |
| Ross, S | 2 |
| Kashifard, M | 2 |
| Basirat, Z | 1 |
| Golsorkhtabar-Amiri, M | 1 |
| Moghaddamnia, A | 1 |
| Colvin, L | 1 |
| Gill, AW | 1 |
| Slack-Smith, L | 1 |
| Stanley, FJ | 1 |
| Bower, C | 1 |
| Abas, MN | 1 |
| Tan, PC | 2 |
| Azmi, N | 1 |
| Omar, SZ | 2 |
| Oliveira, LG | 1 |
| Capp, SM | 1 |
| You, WB | 1 |
| Riffenburgh, RH | 1 |
| Carstairs, SD | 2 |
| Clark, SM | 1 |
| Dutta, E | 1 |
| Hankins, GD | 1 |
| Mills, JR | 1 |
| Greene, DN | 1 |
| Bainton, J | 1 |
| Lorey, TS | 1 |
| Baumann, NA | 1 |
| Siminerio, LL | 1 |
| Bodnar, LM | 1 |
| Venkataramanan, R | 1 |
| Caritis, SN | 1 |
| Fejzo, MS | 1 |
| MacGibbon, KW | 1 |
| Mullin, PM | 1 |
| Boelig, RC | 1 |
| Barton, SJ | 1 |
| Saccone, G | 1 |
| Kelly, AJ | 1 |
| Edwards, SJ | 1 |
| Berghella, V | 1 |
| Reichmann, JP | 1 |
| Kirkbride, MS | 1 |
| McParlin, C | 1 |
| O'Donnell, A | 1 |
| Robson, SC | 1 |
| Beyer, F | 1 |
| Moloney, E | 1 |
| Bryant, A | 1 |
| Bradley, J | 1 |
| Muirhead, CR | 1 |
| Nelson-Piercy, C | 1 |
| Newbury-Birch, D | 1 |
| Norman, J | 1 |
| Shaw, C | 1 |
| Simpson, E | 1 |
| Swallow, B | 1 |
| Yates, L | 1 |
| Vale, L | 1 |
| Edlavitch, SA | 1 |
| Jennings-Sanders, A | 1 |
| Ferreira, E | 1 |
| Gillet, M | 1 |
| Lelièvre, J | 1 |
| Bussières, JF | 1 |
| Raymond, SH | 1 |
| Siu, SS | 1 |
| Yip, SK | 1 |
| Cheung, CW | 1 |
| Lau, TK | 1 |
| Quinla, JD | 1 |
| Hill, DA | 1 |
| Koren, G | 1 |
| Maltepe, C | 1 |
| World, MJ | 1 |
| Tincello, DG | 1 |
| Johnstone, MJ | 1 |
| Sullivan, CA | 1 |
| Johnson, CA | 1 |
| Roach, H | 1 |
| Martin, RW | 1 |
| Stewart, DK | 1 |
| Morrison, JC | 1 |
| Ditto, A | 1 |
| Morgante, G | 1 |
| la Marca, A | 1 |
| De Leo, V | 1 |
| Guikontes, E | 1 |
| Spantideas, A | 1 |
| Diakakis, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Validating the Effect of Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum: A Double-Blind Randomised Placebo-Controlled Multicentre Trial[NCT03785691] | Phase 2 | 58 participants (Actual) | Interventional | 2019-03-01 | Terminated (stopped due to Recruiting difficulties) | ||
| Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum[NCT02163434] | Phase 2 | 31 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Is Zofran Superior to Pyridoxine at Reducing Nausea and Vomiting in Pregnancy[NCT01668069] | 36 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022[NCT06055192] | 200 participants (Anticipated) | Observational | 2023-09-30 | Not yet recruiting | |||
| The Effect of Adjuvant Hypnosis Added to Conventional Therapy on Nausea and Vomiting in Hyperemesis Gravidarum: A Prospective Randomized Study[NCT04828967] | 41 participants (Actual) | Interventional | 2017-01-01 | Completed | |||
| Is the Application of Scopolamine Patch With or Without Intra-operative Acupressure Point P6 Stimulation More Effective Than Intra-operative Acupressure Point P6 Stimulation Alone?[NCT02960113] | Phase 4 | 240 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| IRB-HSR# 14583: Intravenous Ondansetron to Attenuate the Hypotensive, Bradycardic Response to Spinal Anesthesia in Healthy Parturients[NCT01414777] | Phase 2/Phase 3 | 68 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Score range: 6-30 with higher score indicating a worse outcome. (NCT02163434)
Timeframe: 1 week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 6.35 |
| Metoclopramide | 13.22 |
Score range: 2-10 with higher score indicating a worse outcome. (NCT02163434)
Timeframe: 1 week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 2.01 |
| Metoclopramide | 3.69 |
Score range: 0-15 with higher score indicating a better outcome. (NCT02163434)
Timeframe: 1 week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 7.86 |
| Metoclopramide | 4.01 |
Scores: 0=no, 1=yes. Thus, a higher score indicates a better outcome. (NCT02163434)
Timeframe: 1 week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 0.67 |
| Metoclopramide | 0.14 |
Score range: 0-4 with higher score indicating a better outcome. (NCT02163434)
Timeframe: 1 week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 2.22 |
| Metoclopramide | 0.63 |
(NCT02163434)
Timeframe: 1 week
| Intervention | Participants (Count of Participants) |
|---|---|
| Gabapentin | 5 |
| Metoclopramide | 5 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) after eversion of the uterus. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: After eversion of the uterus until replacement of the uterus
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 1.28 |
| Acupressure Point P6 | 1.09 |
| Scopolamine Patch + Acupressure Point P6 | 1.40 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) after replacement of the uterus. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: After replacement of the uterus and to the next 15 minutes
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 2.19 |
| Acupressure Point P6 | 2.19 |
| Scopolamine Patch + Acupressure Point P6 | 2.51 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) after the administration of the regional anesthesia medications. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: From administration of anaesthesia until eversion of uterus
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 2.71 |
| Acupressure Point P6 | 2.57 |
| Scopolamine Patch + Acupressure Point P6 | 2.84 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) upon arrival to the post-operative recovery room. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: 15 minutes after replacement of the uterus to arrival at post-anaesthesia care unit
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 0.18 |
| Acupressure Point P6 | 0.25 |
| Scopolamine Patch + Acupressure Point P6 | 0.23 |
The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea at any point during the surgical procedure in each group. (NCT02960113)
Timeframe: Throughout the entire surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 40 |
| Acupressure Point P6 | 39 |
| Scopolamine Patch + Acupressure Point P6 | 46 |
The investigators will perform objective assessments of whether or not the patients have vomited during the procedure. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: Throughout the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 24 |
| Acupressure Point P6 | 25 |
| Scopolamine Patch + Acupressure Point P6 | 31 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: After eversion of to replacement of the uterus
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 8 |
| Acupressure Point P6 | 6 |
| Scopolamine Patch + Acupressure Point P6 | 9 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: After replacement of the uterus and for next 15 minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 10 |
| Acupressure Point P6 | 15 |
| Scopolamine Patch + Acupressure Point P6 | 12 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: After the administration of the regional anesthesia medications until eversion of the uterus
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 20 |
| Acupressure Point P6 | 15 |
| Scopolamine Patch + Acupressure Point P6 | 20 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: From 15 minutes after replacement of the uterus until arrival at the post-anaesthesia care unit
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 1 |
| Acupressure Point P6 | 1 |
| Scopolamine Patch + Acupressure Point P6 | 4 |
Patients are asked their nausea and vomiting treatment satisfaction (0 = Not Satisfied, 10 = Extremely Satisfied). Patients are also asked their overall satisfaction with the procedure (0 = Not Satisfied, 10 = Extremely Satisfied). (NCT02960113)
Timeframe: Throughout the surgical procedure
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 9.29 |
| Acupressure Point P6 | 8.96 |
| Scopolamine Patch + Acupressure Point P6 | 9.59 |
8 reviews available for ondansetron and Hyperemesis Gravidarum
| Article | Year |
|---|---|
Ondansetron in Pregnancy and the Risk of Congenital Malformations: A Systematic Review.
Topics: Antiemetics; Congenital Abnormalities; Female; Humans; Hyperemesis Gravidarum; Ondansetron; Pregnanc | 2018 |
The outpatient management and special considerations of nausea and vomiting in pregnancy.
Topics: Ambulatory Care; Antiemetics; Diet Therapy; Doxylamine; Female; Fluid Therapy; Gastroesophageal Refl | 2014 |
Ondansetron Use in Pregnancy and Birth Defects: A Systematic Review.
Topics: Abnormalities, Drug-Induced; Antiemetics; Female; Humans; Hyperemesis Gravidarum; Infant, Newborn; O | 2016 |
Interventions for treating hyperemesis gravidarum.
Topics: Acupuncture Therapy; Adrenal Cortex Hormones; Antiemetics; Female; Humans; Hydrocortisone; Hyperemes | 2016 |
Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review.
Topics: Acupuncture; Adrenal Cortex Hormones; Antiemetics; Doxylamine; Female; Histamine Antagonists; Humans | 2016 |
Publishing negative findings and the challenge of avoiding type II errors in studies of suspect teratogens: Example of a recent ondansetron publication.
Topics: Antiemetics; Female; Humans; Hyperemesis Gravidarum; Ondansetron; Pregnancy; Pregnancy Outcome; Rese | 2017 |
Contemporary approaches to hyperemesis during pregnancy.
Topics: Adrenal Cortex Hormones; Antiemetics; Diet; Doxylamine; Female; Humans; Hyperemesis Gravidarum; Obst | 2011 |
Nausea and vomiting of pregnancy.
Topics: Acupressure; Antiemetics; Diagnosis, Differential; Doxylamine; Female; Humans; Hyperemesis Gravidaru | 2003 |
8 trials available for ondansetron and Hyperemesis Gravidarum
| Article | Year |
|---|---|
Validating the effect of Ondansetron and Mirtazapine In Treating hyperemesis gravidarum (VOMIT): protocol for a randomised placebo-controlled trial.
Topics: Antiemetics; Female; Humans; Hyperemesis Gravidarum; Mirtazapine; Multicenter Studies as Topic; Onda | 2020 |
Effect of gabapentin on hyperemesis gravidarum: a double-blind, randomized controlled trial.
Topics: Antiemetics; Female; Gabapentin; Humans; Hyperemesis Gravidarum; Infant, Newborn; Ondansetron; Pregn | 2021 |
Ondansetrone or metoclopromide? Which is more effective in severe nausea and vomiting of pregnancy? A randomized trial double-blind study.
Topics: Adult; Antiemetics; Double-Blind Method; Female; Humans; Hyperemesis Gravidarum; Metoclopramide; Ond | 2013 |
Ondansetron compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial.
Topics: Adult; Antiemetics; Female; Humans; Hyperemesis Gravidarum; Metoclopramide; Ondansetron; Pregnancy; | 2014 |
Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial.
Topics: Adult; Antiemetics; Double-Blind Method; Doxylamine; Drug Therapy, Combination; Female; Follow-Up St | 2014 |
Pre-emptive therapy for severe nausea and vomiting of pregnancy and hyperemesis gravidarum.
Topics: Adult; Antiemetics; Dicyclomine; Doxylamine; Drug Administration Schedule; Drug Combinations; Female | 2004 |
A pilot study of intravenous ondansetron for hyperemesis gravidarum.
Topics: Adult; Antiemetics; Double-Blind Method; Female; Humans; Hyperemesis Gravidarum; Injections, Intrave | 1996 |
Evaluation of treatment of hyperemesis gravidarum using parenteral fluid with or without diazepam. A randomized study.
Topics: Adult; Antiemetics; Diazepam; Female; Gestational Age; Humans; Hydrocortisone; Hyperemesis Gravidaru | 1999 |
17 other studies available for ondansetron and Hyperemesis Gravidarum
| Article | Year |
|---|---|
Ondansetron Use During Pregnancy: Birth Defects and Obstetric Outcomes.
Topics: Antiemetics; Female; Humans; Hyperemesis Gravidarum; Infant, Newborn; Nausea; Ondansetron; Pregnancy | 2023 |
Ondansetron should never be used in pregnancy.
Topics: Antiemetics; Congenital Abnormalities; Female; Humans; Hyperemesis Gravidarum; Ondansetron; Pregnanc | 2021 |
Ondansetron should never be used in pregnancy: Against: Ondansetron in pregnancy revisited.
Topics: Antiemetics; Congenital Abnormalities; Female; Humans; Hyperemesis Gravidarum; Ondansetron; Pregnanc | 2021 |
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Antiemetics; Cannabis; Female; Haloperidol; Humans; Hyperemesis Gravidarum; Ondansetron; Pregnancy; | 2021 |
Gaining Insight Into Ondansetron Safety in Early Pregnancy.
Topics: Antiemetics; Female; Humans; Hyperemesis Gravidarum; Ondansetron; Pregnancy; Pregnancy Trimester, Fi | 2019 |
Off-label use of ondansetron in pregnancy in Western Australia.
Topics: Adult; Antiemetics; Congenital Abnormalities; Female; Humans; Hyperemesis Gravidarum; Infant, Newbor | 2013 |
Fluctuating serum aspartate aminotransferase activity in a complicated pregnancy.
Topics: Adult; Alanine Transaminase; Antiemetics; Aspartate Aminotransferases; Clinical Enzyme Tests; Female | 2015 |
Ondansetron Use in Pregnancy.
Topics: Antiemetics; Female; Humans; Hyperemesis Gravidarum; Ondansetron; Pregnancy; Prenatal Care | 2016 |
Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States.
Topics: Abortion, Spontaneous; Adolescent; Adult; Antiemetics; Child; Congenital Abnormalities; Female; Huma | 2016 |
Ondansetron Use in Pregnancy andOndansetron Use in Pregnancy and Birth Defects: A Systematic Review.
Topics: Antiemetics; Female; Humans; Hyperemesis Gravidarum; Ondansetron; Pregnancy | 2016 |
A case study approach to Hyperemesis Gravidarum: home care implications.
Topics: Adult; Dehydration; Female; Fluid Therapy; Follow-Up Studies; Humans; Hyperemesis Gravidarum; Ondans | 2009 |
Ondansetron use during pregnancy: a case series.
Topics: Adult; Antiemetics; Evidence-Based Medicine; Female; Humans; Hyperemesis Gravidarum; Ondansetron; Pr | 2012 |
A survey of prescribing for the management of nausea and vomiting in pregnancy in Australasia.
Topics: Antiemetics; Australia; Dopamine Antagonists; Female; Histamine Antagonists; Humans; Hyperemesis Gra | 2013 |
Treatment of intractable hyperemesis gravidarum by ondansetron.
Topics: Adult; Antiemetics; Cesarean Section; Diabetes, Gestational; Female; Gestational Age; Hospitalizatio | 2002 |
Ondansetron and hyperemesis gravidarum.
Topics: Adult; Female; Humans; Hyperemesis Gravidarum; Nephritis; Ondansetron; Pregnancy; Pregnancy Complica | 1993 |
Treatment of hyperemesis gravidarum with the 5-HT3 antagonist ondansetron (Zofran).
Topics: Adult; Antiemetics; Female; Humans; Hyperemesis Gravidarum; Ondansetron; Pregnancy; Pregnancy Trimes | 1996 |
Ondansetron and hyperemesis gravidarum.
Topics: Adult; Female; Humans; Hyperemesis Gravidarum; Ondansetron; Pregnancy | 1992 |